[{"orgOrder":0,"company":"SciGen","sponsor":"DKSH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Zoledronic Acid","moa":"||Bone resorption","graph1":"Oncology","graph2":"Approved FDF","graph3":"SciGen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SciGen \/ DKSH","highestDevelopmentStatusID":"15","companyTruncated":"SciGen \/ DKSH"}]

Find Clinical Drug Pipeline Developments & Deals by SciGen

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : DKSH has enetered a strategic partnership with SciGen to supply Zometa (zoledronic acid) to the Vietnamese market. it is indicated for the treatment of Advanced cancers.

                          Product Name : Zometa

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          July 21, 2023

                          Lead Product(s) : Zoledronic Acid,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : DKSH

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Lead Product(s) : Hepatitis B Vaccine Recombinant,Inapplicable

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Undisclosed

                          Recipient : Tel Aviv Sourasky Medical Center (Ichilov Hospital)

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          September 21, 2011

                          Lead Product(s) : Hepatitis B Vaccine Recombinant,Inapplicable

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Recipient : Tel Aviv Sourasky Medical Center (Ichilov Hospital)

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank